HY-PAM 25 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hy-pam 25, and what generic alternatives are available?
Hy-pam 25 is a drug marketed by Teva and is included in one NDA.
The generic ingredient in HY-PAM 25 is hydroxyzine pamoate. There are nineteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the hydroxyzine pamoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hy-pam 25
A generic version of HY-PAM 25 was approved as hydroxyzine pamoate by SANDOZ on December 31st, 1969.
Summary for HY-PAM 25
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HY-PAM 25 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HY-PAM 25
US Patents and Regulatory Information for HY-PAM 25
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva | HY-PAM 25 | hydroxyzine pamoate | CAPSULE;ORAL | 088713-001 | Mar 4, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |